Otsuka puts nearly $1 billion on the line for four neuropsychiatric candidates from Sunovion
It’s been six years since Otsuka got its Lundbeck-partnered antipsychotic Rexulti approved to treat schizophrenia in the US. Now, the company has its sights set on a new approach for the difficult-to-treat disease — and it’s putting down close to $1 billion to snag that candidate and three others from fellow Japanese drugmaker Sumitomo Dainippon Pharma.
Otsuka is shelling out $270 million upfront and another $620 million in biobucks for joint development and commercialization rights to four neuropsychiatric compounds from Sumitomo Dainippon’s subsidiary Sunovion, the companies said on Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.